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ABSTRACT 
The new direct-acting antivirals agents (DAAs) rapidly changed the treatment approach in 
chronic hepatitis C (CHC); however, the interferon (IFN)-free therapies availability is currently 
different in some countries, due to higher costs of these drugs. Naïve treated patients, who are 
not eligible for IFN-free therapies, could be selected for standard dual treatment with pegylated 
(PEG)-IFN and ribavirin (RBV), through  IFN lambda 3  gene polymorphisms and fibrosis 
stage evaluation. 
Inclusion criteria were: naïve treated CHC patients with GT1 or GT4, without major 
contraindication to PEG-IFN or RBV, with fibrosis stage F0-F2 and IFNL3 
rs8099917/rs12979860 TT/CC genotypes. 
65 patients were included in the study. Overall SVR was observed in 50 patients (76.9%); SVR 
rates among different genotypes were as follows: 15 with GT1a (71.4%), 27 with GT1b 
(79.4%) and 8 for GT4 (80%). The RBV cutoff  at 2 weeks of 1800 ng/mL, predictor of RVR, 
was determined (p=0.003; sensibility=60.4%, specificity=88.2%, positive predictive 
value=88.9%, negative predictive value=100%). In multivariate analysis, factors significantly 
associated with treatment failure were living alone condition (OR=4.302; 95%IC=1.254-
16.257; p=0.034) and RBV plasma level < 1800 ng/mL at 2 weeks (OR=4.970; 95%IC=1.405-
17.565; p=0.009).   
Considering a pharmacogenetic-guided approach, dual therapy with PEG-IFN and RBV can be 
considered a reliable option for patients ineligible for IFN-free treatments, who are motivated 
and well informed about all the aspects related to PEG-IFN administration. 
 
Keywords: HCV; genotype 1; genotype 4; PEG-IFN; fibrosis; IL28B 
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1. INTRODUCTION 
In the past two decades, the optimal treatment for chronic hepatitis C infection (CHC) was 
the combination of pegylated-interferon-alpha (PEG-IFN-α) and ribavirin (RBV) 
(McHutchison et al., 1998), though this therapy was less effective in genotype 1 (GT1) and 
affected by several side-effects (subcutaneous administration and the long term of 
completion of  24 or 48 weeks) (Antonini et al., 2008; W, 2002).  The recent introduction of 
well-tolerated oral agents (the direct-acting antivirals, DAAs), with a direct suppression of 
the HCV replication,  has completely changed the current approach to CHC treatment. In 
fact, they can consist in IFN-free regimens, without significant adverse events (AEs), a low 
pill burden and shorter therapy duration (Carrion et al., 2014). Therefore, to date, PEG-IFN 
is falling out of use and not indicated as the first-line treatment in the clinical practice 
guidelines (EASL, 2015). The main limitation of the IFN-free regimens is the high cost, 
which limits the availability especially in developing countries (Rein et al., 2015); anyway, 
the restriction policies have also been established in several European states (van de Vooren 
et al., 2014; Zoulim et al., 2015). In Italy, the Italian Drug Agency (AIFA) approved IFN-
free therapies only for patients showing advanced liver fibrosis or cirrhosis, whereas patients 
showing mild fibrosis stage could be treated only with PEG-IFN and RBV regimens 
((AIFA)). Consequently, patients who are not eligible for DAAs may have two options: the 
first one is to wait a future conceivable extension of inclusion criteria for lower costs of 
drugs treatment; the second one is to accept the standard treatment. In the latter case, 
however, the IFN-based treatment should be optimized using an appropriate selection of 
patients: who may achieve the sustained virological response (SVR), avoiding the IFN 
administration in presence of poor chances of response, risk of severe side-
effects/contraindication or limited compliance.  
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In a retrospective analysis, we selected GT1 and genotype 4 (GT4) patients considering fibrosis 
stage, IFN lambda 3 (IFNL3,  previously known as IL28B) gene genotypes and the rapid 
virological response (RVR) achievement. In GT1 naïve patients treated for 48 weeks with PEG-
IFN and RBV, without severe fibrosis or cirrhosis and IFNL3 rs8099917/rs12979860 TT/CC 
genotypes, SVR was 98% (Boglione et al., 2015). In GT4 naïve patients with the same baseline 
characteristics, SVR was 88.8% (Boglione et al., 2014), with a strong association between the 
IFNL3 genotype and the HCV-RNA baseline levels (Boglione et al., 2016).  
We decided to analyze IFNL3 rs8099917/rs12979860 TT/CC, because different studies showed 
that these two polymorphisms (which are in moderate linkage disequilibrium (r
2
=0.41, in our 
Italian cohort) were associated with a greater likelihood of HCV persistence, particularly in 
HCV GT1 and GT4 (Aparicio et al., 2010; Bitetto et al., 2011; Boglione et al., 2015; Boglione 
et al., 2014).  
The main aim of this prospective study was the evaluation of effectiveness of standard dual 
therapy in GT1 and GT4 naïve treated patients (a real-life population), who are currently not 
eligible for novel IFN-free regimens, according to fibrosis stage and IFNL3 gene genotypes.  
 
2. METHODS 
2.1 End-points and study design 
This was a prospective, pharmacogenetic, pharmacokinetic single-centre study conducted at the 
Unit of Infectious Disease, “Amedeo di Savoia Hospital” in Turin, Italy. Patients enrollment 
started in June 2014 and ended in May 2015. The study protocol was approved by our local 
Ethic Committee in 23/6/2014 as “In Riba Veritas” study and it was conducted in compliance 
with the Declaration of Helsinki and with the local Review Board regulations. 
Inclusion criteria were: naïve CHC patients with GT1 or GT4, HIV uninfected, without major 
contraindication to PEG-IFN or RBV, with fibrosis stage F0-F2 (Metavir score) and IFNL3 
rs8099917/rs12979860 TT/CC genotypes. All the patients have been informed of the alternative 
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option of waiting for the novel IFN-free therapies, when available, and they gave an informed 
consent before the study inclusion. 
All the patients screened for this study provided a questionnaire describing the reason for 
accepting or refusing treatment. 
Primary end-point of this study was the SVR evaluation; secondary aims were the side-effects 
analysis, the treatment interruption due to toxicity, RBV pharmacokinetic (PK) analysis at 
selected time-points. 
All the patients were treated using PEG-IFN-α 2a once-weekly through subcutaneous injection 
at the dose of 180 μg (Pegasys®, Roche) or PEG-IFN-α 2b 1.5 µg/kg/week with RBV at 15 
mg/kg/day for 48 weeks. All the patients were followed for 6 months after the treatment 
completion.  
SVR was defined as HCV-RNA undetectable 24 weeks after treatment completion; rapid 
virological response (RVR) was defined as HCV-RNA undetectable after 4 weeks of therapy; 
early virological response (EVR) as HCV-RNA negative after 12 weeks. Treatment failure was 
defined by the lack of SVR: null-responders (NR), when the decrease of HCV-RNA after 12 
weeks of therapy was less than 2 log; partial responders (PR), if HCV-RNA decrease was more 
than 2 log after 12 weeks, but still detectable at week 24; relapsers (REL), when HCV-RNA 
was undetectable at treatment completion, but positive in the follow-up without re-infection; 
treatment was discontinued in NR at week 12 and in PR at week 24.  
Safety evaluation was performed according to WHO grading scale (WHO, 2003). 
HCV-RNA quantification was performed after 1 and 2 weeks and monthly until the end of 
therapy.  
Fibrosis stage was evaluated as METAVIR Fibrosis Score using transient elastography 
(Fibroscan
®
, Echosens, Paris, France); according to liver stiffness cut-off values reported in 
Castéra et al.: F0<5.0 kPa; F1: 5.1-7.0 kPa; F2: 7.1-9.4 kPa; F3: 9.5-12.4 kPa; F4>12.5 kPa 
(Castera et al., 2005). 
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2.2 Pharmacogenetic analysis  
 IFNL3 rs8099917 and rs12979860 polymorphisms were determined with Taq Man Drug 
Metabolism Genotyping Assays (TaqMan MGM probes, FAM and VIC dye-labeled, Applied 
Biosystems by Life Technologies, Carlsbad, California, US), using a real-time polymerase 
chain reaction allelic discrimination system (Bio-Rad Real-time thermal cycler CFX96), with a 
standard procedure (primers, probes and PCR conditions available on request). 
 
2.3 Pharmacokinetic analysis 
RBV plasma level measurement was performed at the end of dosing interval, before the 
assumption of the new dose (Ctrough) at 1 and 2 weeks of treatment and then monthly, until 6 
months of therapy. RBV quantification has been performed through a previously published 
HPLC-UV method (D'Avolio et al., 2006). 
 
2.4 Statistical analysis 
PK data have been described as median values and interquartile ranges (IQR). 
Differences between two groups have been tested through non parametric Mann-Whitney test. 
Intra-patient differences at different timings have been evaluated through Wilcoxon test for 
paired samples. 
Correlations between continuous variables have been evaluated by bivariate Pearson correlation 
test, whereas Spearman one was considered for correlations between ordinal categorical and 
continuous variables. Univariate logistic regression has been performed in order to test the role 
of single variables for treatment failure: only variables with a P value lower than 0.2 have been 
tested in the multivariate analysis. P values lower than 0.05 have been considered statistically 
significant. Finally, receiver operating characteristic (ROC) curve has been used in order to 
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determine RBV cutoff values for RVR. All the statistical tests have been performed through 
SPSS version 22.0. 
  
3. RESULTS 
3.1 Patients selection and baseline characteristics 
A total of 174 CHC GT1 or GT4 patients were screened in the enrollment period; 41 were 
excluded for a fibrosis stage > F2, 9 experienced, 27 for a different IFNL3 genotype compared 
to TT/CC one and 32 refused the treatment option with PEG-IFN and RBV. Thus, 65 patients 
were finally included in the study (Figure 1). 
Baseline characteristics of the study population were reported in Table 1. Male patients were 47 
(72.3%), Italians 42 (64.6%); the most frequent risk factor for HCV detection was intravenous 
drug use (IDU) in 25 patients (38.5%) with 16 patients on treatment with methadone or 
buprenorphine (24.6%). Among socio-economic factors, we observed that unemployed subjects 
were 31 (47.7%), 14 live alone (21.5%), 9 had a previous detention (13.8); median time of 
schooling was 8 years, with an observed low level in 19 (29.2%). Alcohol consumption was 
reported in 41 (63%) patients.  
Reasons of 32 patients who refused treatment were represented in figure 2: many of them (16, 
50%) have chosen to wait new therapies, when available.  
 
3.2 Treatment outcomes 
Overall SVR was observed in 50 patients (76.9%); SVR rates among different genotypes were 
as following: 15 with GT1a (71.4%), 27 with GT1b (79.4%) and 8 for GT4 (80%) (Figure 3). 
HCV-RNA was undetectable after 2 weeks of therapy in 13 patients (20%) and RVR was 
achieved in 7 (10.8%) ones; all the RVR patients at 2 weeks and 1 month gained the SVR. 
Early virological response (EVR) was observed in 40 patients without RVR (61.5) and 27 of 
them (67.5%) achieved SVR. The 13 patients without EVR were: 2 (3%) NR (treatment 
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stopped at 12 weeks), 1 (1.5%) PR (treatment stopped at 24 weeks) and 5 (7.7%) with relapse 
after treatment completion (Table 2). Other 3 patients interrupted treatment before the 12 weeks 
(drop-out) for side-effects and poor adherence. The other 4 drop-out patients stopped the 
treatment after 12 weeks: 2 patients for physicians’ decision (grade 2 of anemia with severe 
symptoms) and 2 for own choice, due to difficult life conditions or professional limitations 
related to PEG-IFN side-effects. 
 
3.3 Side-effects and treatment interruption 
The observed side-effects during treatment were described in Table 2. Anemia and neutropenia 
were the most common laboratory detected abnormalities (20 and 13.8%, respectively); 2 
patients with grade 2 anemia interrupted treatment after 12 weeks for clinicians’ decision, due 
to severity of the symptoms (fatigue and movement difficulties). The management of 11 
patients with grade 1 anemia has been performed with only RBV dose  reduction (n=6), epoetin 
beta administration (n=2) and with both reduction and growth factors (n=3). Neutropenia was 
prevalent in patients treated with PEG-IFN-α 2a (8 vs 1) and it was solved with dose adjustment 
from 180μg to 135μg. No serious adverse effects were reported. Flu-like syndrome was the 
most prevalent self-reported trouble in 28 patients (43%) with associated fatigue (50.7%) and 
weight loss (27.7%).  
5 drop-out patients (3 before and 2 after 12 weeks of treatment) were observed, due to PEG-
IFN related side-effects affecting life or job conditions.  
 
3.4 RBV pharmacokinetic  
RBV plasma concentrations at 1 and 2 weeks were significantly related to HCV-RNA 
undetectability (p<0.001); median RBV values at 2 weeks of treatment were 1438 ng/mL in 
patients without undetectable HCV-RNA and 2687 ng/mL in negative HCV-RNA ones 
(p<0.001) (Figure 4).    
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Median RBV values at 2 weeks and 1 month of treatment resulted significantly higher in 
patients who gained SVR compared to patients who failed treatment (Figure 5); at 2 weeks 
RBV values were: 1849 ng/mL in SVR, 809 ng/mL in NR-PR and 1020 ng/mL in REL 
patients; at 1 month 1979 ng/mL in SVR, 907 in NR-PR, 1070 in REL (p<0.001 for all groups) 
ones. 
Finally, receiver operating characteristic (ROC) curve has been used in order to determine the 
RBV cutoff  at 2 weeks of 1800 ng/mL, predictor of RVR (p=0.003; sensibility=60.4%, 
specificity=88.2%, positive predictive value=88.9%, negative predictive value=100%).  
 
3.5 Univariate and multivariate analysis for treatment failure 
We have focused the attention on treatment failure (Table 3), since higher rates of SVR were 
observed in this study. In univariate analysis, following factors were related to treatment 
failure: GT1a (OR=2.393; 95%IC=0.761-7.524; p=0.135), living alone condition (OR=4.100; 
95%IC=1.169-14.384; p=0.028), RBV level below 1800 ng/mL at 2 weeks of therapy 
(OR=4.800; 95%IC=1.441-15.993; p=0.011). In multivariate analysis, factors significantly 
associated with treatment failure were living alone condition (OR=4.302; 95%IC=1.254-
16.257; p=0.034) and RBV plasma level < 1800 ng/mL at 2 weeks (OR=4.970; 95%IC=1.405-
17.565; p=0.009).   
 
4. DISCUSSION 
The current use of dual therapy with PEG-IFN and RBV is often limited by the spread of novel 
DAAs and IFN-free regimens; however, the problem of high costs of these treatments leads to 
different availability in many areas of the world, especially in developing countries. Moreover, 
in most cases, the IFN-free regimens were administered only in patients with advanced hepatic 
fibrosis or cirrhosis (Chhatwal et al., 2015; Messori et al., 2014). Two different options are now 
available for patients, who were excluded from new treatments: waiting for future therapies or 
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the administration of standard dual therapy with PEG-IFN and RBV. Some recent studies 
examined the patients choices about the treatment decision; interestingly, treated naïve patients, 
with lower fibrosis stage, accepted treatment more than others. The main cause of treatment 
refusal in experienced or cirrhotic patients was the fear of IFN-related side-effects (Feillant et 
al., 2015). Other causes of delayed or refused treatment could be the socio-economic 
conditions, language barriers or schooling level, and especially the employment status 
(Niederau et al., 2012). In our analysis of 32 patients, who refused the PEG-IFN treatment 
option, the most relevant refusal reasons were the waiting for IFN-free regimens (50%) and the 
fear of PEG-IFN toxicity (31.2%) (Figure 2). However, our selection excluded the experienced 
patients with severe hepatic fibrosis and, among 97 screened subjects with all the inclusion 
criteria, 65 accepted to start treatment (67%).  
Treatment desire was more often related to young age, social conditions, patient motivation, 
ability to understand the most common side-effects and pregnancy planning for female patients, 
as previously observed in several studies (Shiffman and Benhamou, 2013).   
Therefore, dual therapy should be optimized in patients with selected characteristics in order to 
improve the effectiveness and minimize the problems related to PEG-IFN or RBV 
administration. Based-on previous analyses in GT1/4 dual therapy treated patients , we 
identified an increased SVR rate in a population showing the following characteristics: naïve 
treatment, with IFNL3 TT/CC genotypes, low fibrosis stage and RVR achievement (Boglione et 
al., 2015; Boglione et al., 2014). Our results confirmed the effectiveness of dual therapy in this 
selected population; the overall SVR achievement was similar to that reported in retrospective 
analyses, despite the presence of drop-out patients. This high rate of response and the global 
low impact of toxicity on treatment interruption (10.8%) showed that PEG-IFN and RBV can 
still be a valuable therapeutic option in a selected group. However, the management of side-
effects represents an important factor for avoiding treatment interruption; all the patients should 
be well informed about all the aspects related to PEG-IFN and RBV toxicity and their 
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consequences in everyday life. Therefore, in our study, we analyzed all the possible socio-
economic conditions related to treatment interruption (considering the patient choice). 
Interestingly, the possible barriers as low schooling level, previous imprisonment, active IDU, 
unemployed status, methadone or buprenorphine assumption were not predictors of treatment 
failure, whereas patients who live alone evidenced a higher drop-out risk. This novel finding 
could be related to difficult PEG-IFN management (as well as subcutaneous administration or 
the drug storage in the refrigerator) in complicated living conditions. For these reasons, patients 
who live alone may not be the ideal candidates for this therapy and should waiting for the novel 
IFN-free regimens, when available.  
RBV plasma level pharmacokinetic analysis confirmed the important role of this drug 
concentrations for RVR and SVR prediction (D'Avolio et al., 2012); consequently, we 
recommended the RBV weight-based dose (15 mg/Kg/day) and, when possible, the plasma 
measurement at 2 weeks for dose adjustment, considering a level below the optimal cut-off 
related to treatment response (1800 ng/mL). 
The current use of IFN-based therapies is debated (Feld, 2014); IFN-free regimens are really 
promising and desirable for higher effectiveness and low toxicity, but in many countries, they 
are currently unavailable. Therefore, in patients with selected genetics, clinical characteristics 
and with a strong motivation, the dual therapy administration may be the only current available 
option  in resource-limited settings.        
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Figure legends 
Figure 1. Flow of enrolled patients in the study 
Figure 2. Reasons for treatment refusing  
Figure 3. Ouctomes of treatment according to HCV genotypes 
Figure 4. RBV median plasma concentration (ng/mL) of treatment in patients with and without 
HCV-RNA undetectable at 2 weeks of treatment. 
Figure 5. RBV median plasma concentration (ng/mL) among different virological outcomes 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
16 
 
 
Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Table 1. Baseline characteristics of study population 
Patients characteristics N=65 
Gender: male, n (%) 47 (72.3) 
Age (yr) 43 [35-50.5] 
Ethnic group, n (%) 
            Italian  
            Egyptian 
            East-Europe       
            Africa 
 
42 (64.6) 
8 (12.3) 
14 (12.3) 
1 (1.5) 
Risk factors for HCV n (%) 
            Unknown 
            Sexual exposure 
            IDU 
            Blood transfusion 
 
18 (27.7) 
8 (12.3) 
25 (38.5) 
14 (21.5) 
Methadone or buprenorphine assumption 
N (%) 
16 (24.6) 
Alcohol consumption n (%) 
None 
< 20 g/day 
20-50 g/day 
>50 g/day 
 
24 (36.9) 
17 (26.1) 
16 (24.6) 
8 (12.3) 
Years of schooling 
Low schooling level (<5 years) 
8 [5-10.5] 
19 (29.2) 
Patients unemployed  31 (47.7) 
Patients living alone 14 (21.5) 
Patients with previous detention  9 (13.8) 
BMI (kg/m
2
)  
BMI>25 
BMI>30
 
25 [22.8-27.1] 
33 (50.8) 
4 (6.2) 
Liver stiffness (kPa) 6.7 [5.2-7.8] 
Fibrosis stage [Metavir score], n (%) 
       0 
       1 
       2 
 
13 (20) 
45 (69.2) 
7 (10.8) 
Alanine aminotransferase (ALT) [IU/ml] 75 [43-121] 
HCV genotypes  n (%) 
1a 
1b 
4 
 
21 (32.3) 
34 (52.3) 
10 (15.4) 
HCV-RNA [LogIU/ml] 
HCV-RNA>600.000 IU/mL 
6.1 [5.6-6.4] 
43 (66.2) 
Cryoglobulinemia n (%) 30 (46.2) 
Insuline resistance n (%) 22 (33.8) 
Diabetes  n (%) 9 (13.8) 
PEG-IFN α-2a  
Dose: 180μg/week 
PEG-IFN α-2b 
Dose: 50μg/week 
          80μg/week 
41 (63.1) 
41 (63.1) 
24 (36.9) 
1 (1.5) 
8 (12.3) 
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Table 2. Treatment outcomes, laboratory abnormalities and side-effects observed  in the study 
population 
Outcome N, % 
HCV-RNA undetectable at 2 weeks 13 (20) 
RVR 7 (10.8) 
EVR 40 (61.5) 
SVR 50 (76.9) 
Null-responders 2 (3) 
Partial-responders 1 (1.5) 
Relapser 5 (7.7) 
Drop-out 7 (10.8) 
Laboratory abnormalities and side-effects N, % 
Anemia, any grade 
Grade 1 
Grade 2 
13 (20) 
11 (16.9) 
2 (3) 
Neutropenia, any grade 
Grade 1 
Grade 2 
9 (13.8) 
6 (9.2) 
3 (4.6) 
Flu-like syndrome 28 (43) 
Fatigue 33 (50.7) 
Anxiety, depression, insomnia 8 (12.3) 
Weight loss 18 (27.7) 
Hair loss 8 (12.3) 
 
 
 
 
 
 
 
 
          100μg/week 
          120μg/week 
          150μg/week 
4 (6.2) 
7 (10.8) 
4 (6.2) 
Ribavirin dose (mg/day) 
800 mg 
1000 mg 
1200 mg 
1400 mg 
 
16 (24.6) 
34 (52.3) 
13 (20) 
2 (3.1) 
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Table 3. Univariate and multivariate analysis for treatment failure 
 
 
 
 
 
 
  
Univariate analysis 
Factors OR, 95% IC, p 
Age >50 1.835 (0.522-6.098) p=0.322 
Sex M 0.611 (0.186-2.009) p=0.417 
Genotype 1a 2.393 (0.761-7.524) p=0.135 
High viral load 0.649 (0.207-2.036) p=0.459 
PEG-IFN alfa (2a vs 2b) 1.276 (0.411-3.962) p=0.673 
Italian origin 1.440 (0.436-4.761) p=0.550 
Active IDU 0.833 (0.263-2.631) p=0.755 
BMI >25 1.553 (0.507-4.757) p=0.441 
Insuline resistance 1.091 (0.341-3.486) p=0.883 
Diabetes 1.500 (0.331-6.805) p=0.599 
Low schooling level  1.469 (0.451-4.784) p=0.524 
Previous imprisonment 1.534 (0.315-5.908) p=0.533 
Unemployed 1.035 (0.342-3.134) p=0.951 
Living alone 4.100 (1.169- 14.384) p=0.028 
Methadone or buprenorphine 1.402 (0.405-4.851) p=0.594 
[RBV] at 2 weeks of therapy < 1800 ng/mL 4.800 (1.441-15.993) p=0.011 
  
Multivariate analysis  
Factors OR, 95% IC, p 
Genotype 1a 1.953 (0.550-6.942) p=0.301 
Living alone 4.302 (1.254-16.257) p=0.034 
[RBV] at 2 weeks of therapy < 1800 ng/mL 4.970 (1.406-17.565) p=0.009 
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Highlights 
 
 The IFN-free therapies are currently not available for all patients due to higher  costs.  
 The standard dual therapy with PEG-IFN and RBV could be use in selected patients 
who are ineligible for IFN-free regimens. 
 In naïve patients with genotypes 1a, 1b or 4,  F0-F2 and IL28B TT/CC the higher 
chance of SVR encourage the treatment. 
 Management of  side-effects and social or life conditions of patients are important 
factors to consider before treatment. 
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